News | April 29, 2025
Indegene posts Q4 FY25 consolidated PAT at Rs. 117.6 Cr
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
Delivers robust earnings performance, successfully navigating a dynamic environment
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
The 27 greenfield labs across the country ensure timely and accurate reporting
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Subscribe To Our Newsletter & Stay Updated
